ライフサイエンスコーパス: follow-up period

1 d monthly after injection during the 6-month follow up period.

2 ents had the highest SMRs (>2-5) through the follow up period.

3 a had the highest SMRs ( > 5-10) through the follow up period.

4 ative change in impulsivity over a six month follow up period.

5 and new infection occurring during the trial follow up period.

6 disease event or mortality over the 12 month follow up period.

7 ersus alive 1 year after ECG) over a 25-year follow-up period.

8 61% developed new episodes of AKI during the follow-up period.

9 to treatment allocation until the end of the follow-up period.

10 nature of the measures and relatively short follow-up period.

11 ved at least three lines, during the 6-month follow-up period.

12 or 4 months remained stable over the 8-month follow-up period.

13 udy outcomes have occurred or the end of the follow-up period.

14 patients, 1,839 (64.1%) survived the 3-year follow-up period.

15 extrapolated over a larger sample and longer follow-up period.

16 sustained 630 adjudicated CVEs over a 5-year follow-up period.

17 cations occurred in 56.4% of eyes during the follow-up period.

18 l confusion; the symptoms disappeared in the follow-up period.

19 d but the diarrhea persisted during a 4-week follow-up period.

20 d comparable glycemic control throughout the follow-up period.

21 ibody titres approaching baseline within the follow-up period.

22 essment followed by a 12-month observational follow-up period.

23 ily cannabis use during at least one 6-month follow-up period.

24 and incidence of regression over a one-year follow-up period.

25 pes of diabetic macular edema over a 6-month follow-up period.

26 resource utilization endpoints through this follow-up period.

27 ese children 7 to 12 years old over a 4-year follow-up period.

28 chronic kidney disease during the 12.5-year follow-up period.

29 hree patients (19.4%) died during the 1-year follow-up period.

30 ostal-code addresses in each year during the follow-up period.

31 grafts (FGG) at implant sites over a 3-month follow-up period.

32 riodontal pocket development over an 11-year follow-up period.

33 confers a survival benefit after an extended follow-up period.

34 onths after the trial ended, at the 18-month follow-up period.

35 The authors identified 129 events during the follow-up period.

36 urther bleeding and anemia at the end of the follow-up period.

37 gher on cervical biopsy, during the 24-month follow-up period.

38 al detachment developed in 7 eyes during the follow-up period.

39 rious adverse events was reported during the follow-up period.

40 clinical gains continued during the 6-month follow-up period.

41 first dose and were sustained throughout the follow-up period.

42 ed on follow-up for the entire treatment and follow-up period.

43 and the comparison cohort during the 10-year follow-up period.

44 he occurrence of a flare during the 24-month follow-up period.

45 fficacy were also recorded at the end of the follow-up period.

46 =30%, respectively, through years 2-8 of the follow-up period.

47 usion abnormalities, and 25% died during the follow-up period.

48 y signals were observed during the long-term follow-up period.

49 ability in perceived stress during a 4-month follow-up period.

50 nd ASCVD prognostic indicators during a long follow-up period.

51 ized at the time of diagnosis and during the follow-up period.

52 clinical signs of bowel ischaemia during the follow-up period.

53 walking speed (yes or no) during the 4-year follow-up period.

54 6 years, 939 had at least 1 x-ray during the follow-up period.

55 onth treatment period, followed by a 6-month follow-up period.

56 Rate of MD change during follow-up period.

57 of >/=2 dilutions (4-fold) during a 12-month follow-up period.

58 ve changes in glycemic indicators during the follow-up period.

59 high-risk real-world cohort during a midterm follow-up period.

60 t least once while 22 (7.9%) died during the follow-up period.

61 erence in VFI was calculated for the 3 years follow-up period.

62 ease-modifying therapy) across the 6-10 year follow-up period.

63 nts for most patients with CSU over a 2-year follow-up period.

64 to 0.31 +/- 0.13 D (P = .732) at the 1-year follow-up period.

65 th a health-care provider within a specified follow-up period.

66 (- 1.25 dB) glaucoma group in the three-year follow-up period.

67 ated complications (12.3%) were noted in the follow-up period.

68 ed a physician-made BCC diagnosis during the follow-up period.

69 relatives with bloodstream infection in the follow-up period.

70 nts (5.3%) required lead revision during the follow-up period.

71 iac events (MACE) was assessed over a 1-year follow-up period.

72 neal failures were found during the 24-month follow-up period.

73 efined as event occurrence status during the follow-up period.

74 follow-up period but within the optional 1-y follow-up period.

75 tiveness of LAA closure devices in a midterm follow-up period.

76 ent in asymptomatic fecal samples during the follow-up period.

77 or placebo daily for 4 weeks with an 8-week follow-up period.

78 per 1000 person-years) during a 5-year mean follow-up period.

79 ack of viral load data, and relatively short follow-up period.

80 ll disease were reduced or absent during the follow-up period.

81 effect, we analysed the results in different follow-up periods.

82 during the 12-week intervention and 3-month follow-up periods.

83 0-0.50) and remained at 20/30 throughout all follow-up periods.

84 ember 2, 2016, with 3-month intervention and follow-up periods.

85 014 to 2015 (54.6%) and 2016 to 2017 (40.4%) follow-up periods.

86 During the follow-up period, 154 patients (5.7%) developed HGD or E

87 with 4,923 incident cases during a 16.7-year follow-up period (1993-2013).

88 on of Diseases code 367.1) during the 4-year follow-up period (2010-2013) after excluding prevalent c

89 RSSRs during a baseline (2012-2013) and two follow-up periods (2014-2015 and 2016-2017).

90 nts, there were 314 deaths during the entire follow-up period (204 deaths in the original trial and 1

91 of corneal transplants had failed within the follow-up period (21.8 +/- 11.4 months), and 75.9% of ey

92 n patients who had a relapse during the 6-mo follow-up period (+25.1%).

93 During the follow-up period, 28 of 158 (18%) lesions spontaneously

94 t our inclusion criteria, during the 10-year follow-up period, 28,655 (0.52%) were diagnosed with mit

95 Over the median 3.1-year follow-up period (302,526 person-years), 732 deaths were

96 who received health screenings over a 5-year follow-up period; 317 incidents of MS (16.1%) were obser

97 During the follow-up period, 33 eyes underwent treatment.

98 Over the 48-week follow-up period, 35 (9%) died or were lost-to-follow-up

99 Inadequate follow-up period (37% of excluded cases) was the most co

100 Through the 10-year follow-up period, 398 individuals with tinnitus (3.1%) a

101 383 children who returned for the full 12-mo follow-up period, 407 children (56%) and 347 children (5

102 During the follow-up period, 42 (15%) of 280 children developed vil

103 During the 30-y follow-up period, 680 participants developed T2D.

104 2 versus 1/147; P<0.001) or die during study follow-up period (7 versus 0; P=0.007).

105 patients (mean age: 61.8 +/- 7.1 years; mean follow-up period: 9.0 +/- 2.5 months).

106 associated with mortality over the surgical follow-up period (90D mortality 1.7% vs 2.1%; P = 0.06).

107 implantation was 41.0 (11.4) years, and the follow-up period after implantation was 3.2 (3.8) years.

108 rgoing screening mammography within a 2-year follow-up period among the 3 groups.

109 rates of cognitive decline over an 18 month follow up period and conversion to dementia over a 5.5 y

110 lowing myopia progression over a twelve-year follow-up period and demonstrated a clinically acceptabl

111 suicide since first hospital presentation by follow-up period and estimated the association between i

112 ween weekly urine drug screens over a 90-day follow-up period and fNIRS, craving, and HAM-D assessmen

113 of their baseline examination and during the follow-up period and had at least 1 follow-up CT scan, a

114 Limitations include a relatively short follow-up period and use of outcome assessors who were n

115 rosthetic joints, 1 PJI developed during the follow-up period and was classified as a 'missed' PJI at

116 prise a small number of patients, have short follow-up periods, and lack pathologic confirmation of t

117 been limited by convenience sampling, short follow-up periods, and the inability to account for comb

118 e been done had small sample sizes and short follow-up periods, and used earlier versions of the pred

119 o hospital with self-harm during the 6-month follow-up period; and cost-effectiveness of the VHS as m

120 er, a larger number of patients and a longer follow-up period are needed to confirm our results.

121 P. falciparum infections returned during the follow-up period as the remaining infections spread and

122 tic P vivax parasitaemia during the 12-month follow-up period, assessed in the intention-to-treat pop

123 depressive symptoms in adulthood during all follow-up periods (beta = 0.07, P = 0.001) than living i

124 developed progressive disease after the 6-mo follow-up period but within the optional 1-y follow-up p

125 vere adverse events were detected during the follow-up period, but none was attributable to the inter

126 from 14 birth cohort studies (each with 3-20 follow-up periods) carried out in 9 European countries d

127 measured every 2-3 months during a 14-month follow-up period (children could migrate into or out of

128 ected visual acuity (BCVA) at the end of the follow-up period compared to baseline.

129 associated with Crohn's diagnosis during the follow-up period compared with the normal group (19% vs

130 iTIs Study (VEKTIS), 142 entered the 8-month follow-up period during which CsA CE patients remained o

131 The 18-month follow-up period ended in March 2018.

132 The follow-up period for all arrhythmias was from surgery un

133 lizations were collected during the complete follow-up period for each patient.

134 The mean follow-up period for GA MRI examinations performed in pa

135 The mean follow-up period for incident events was 12.5 years, fro

136 During the 6 months follow-up period, four relapses were documented, one in

137 s stayed in the same cluster over the 5 year follow-up period, from 92.1% in the Nervous, Musculoskel

138 During both follow-up periods, >70% of top-performing hospitals rank

139 associated with a diagnosis of CD during the follow-up period (hazard ratio, 3.03; 95% CI, 1.64-5.63;

140 higher risk for mortality during the 2-year follow-up period (hazard ratio: 1.51; 95% confidence int

141 Over the 10-year follow-up period, HF occurred in 512 (3.3%) participants

142 2%) of 4074 matched controls died during the follow-up period (HR 2.78, 95% CI 0.95-8.11, p=0.061).

143 sent at baseline reverted to normal over the follow-up period in 11 (6%).

144 Over a 24-week follow-up period in 47 children on 30 mg dispersible tab

145 pairment but remained stable over the entire follow-up period in 8 out of the 9 control elderly subje

146 At the end of the follow-up period in Dec 31, 2017, median follow-up was 6

147 aseline, 117 developed AF during the 20-year follow-up period (incidence rate, 8.2; 95% CI, 6.8-9.6 p

148 Follow-up period included Medicare coverage until death,

149 s were predictive of mortality at the end of follow up period, including advanced age [odds ratio (OR

150 Data including patients' age, sex, length of follow-up period, initial tooth prognosis, revised tooth

151 The follow-up period lasted 6 months to record the next seve

152 fractive quadrifocal IOL implantation with a follow-up period longer than six months and records of w

153 ival analysis for countries with data in the follow-up period (March 22, 1989, to Feb 2, 2018) to ass

154 vascular disease diagnosis, death, or end of follow-up period (March 31, 2016).

155 Larger studies with longer follow-up periods may be required to confirm these findi

156 visit (1.0 vs 2.0; p=0.008), despite similar follow-up periods (mean, 73.9 months vs 73.4 months), th

157 During the follow-up period (median = 12.4 mo; interquartile range,

158 was the development of malignancy within the follow-up period (median, 6.5 years).

159 who worsened in upper limb function over the follow-up period (n=9, p=0.002).

160 r CIED-related infections through the entire follow-up period occurred in 32 patients in the envelope

161 ce of complications were documented during a follow up period of 2 years.

162 hich 371 (36%) received a RT during a median follow up period of 2,5 (1.4-4.1) years.

163 ar in a cohort of 538 patients with a median follow up period of 4.1 years.

164 Over a total follow-up period of 1 373 131 patient-years (PYs), 31 45

165 urgeries were enrolled over 9 months, with a follow-up period of 10 to 14 days.

166 atients was -0.12+/-0.51 dB/year over a mean follow-up period of 10.4+/-3.7 years.

167 Over a follow-up period of 12 months, 15 of 73 (20.5%) subjects

168 by food-frequency questionnaire.Over a mean follow-up period of 12.4 y, 3259 (31%) deaths occurred.

169 Overall, there was a mean follow-up period of 1244.2 days (+/- 756.7) and a total

170 d its major subtypes identified after a mean follow-up period of 14 years (through 2015).

171 mortality of 4.4% over 4 years with a total follow-up period of 15,500 days for the entire cohort.

172 During a mean (SD) follow-up period of 16.7 (3.2) years, 6,587 participants

173 During a mean follow-up period of 16.7 years, we identified 4,879 inci

174 and 2 cities in the United States and with a follow-up period of 17 years (1995-2011), was linked to

175 rmined by disease-specific survival during a follow-up period of 17 years.

176 an appropriate control group with a minimum follow-up period of 18 months.

177 ely documented venous thromboembolism over a follow-up period of 180 days.

178 and no graft loss was observed over a medium follow-up period of 19 months.

179 f the primary and secondary endpoints over a follow-up period of 2 years was low in both the control

180 ich 371 (36%) received an RT during a median follow-up period of 2.5 (1.4-4.1) years.

181 ubjects had an ischemic stroke over a median follow-up period of 2.5 years.

182 atients, 9% of patients died within a median follow-up period of 2.9 years: 342 (3.1%) during treatme

183 ates were 64.7% in the postoperative average follow-up period of 24 months.

184 After a median follow-up period of 26 months (interquartile range, 20-3

185 ents (2.15 IEps per patient) during a median follow-up period of 3 years.

186 were included in the analysis with a median follow-up period of 3.0 years, of whom 230 (7.2%) had ex

187 After a median follow-up period of 3.6 years, the composite end point w

188 During the median follow-up period of 31 (interquartile range 19;61) month

189 Over a mean follow-up period of 34 months with 49,299 person-years,

190 ch was well tolerated in all patients over a follow-up period of 4 wk.

191 During the median follow-up period of 4 years, 25 patients (24.5%) showed

192 During a median follow-up period of 4 years, 8% (21 of 259) experienced

193 ar in a cohort of 538 patients with a median follow-up period of 4.1 years.

194 Over a median follow-up period of 4.7 years, baseline statin use was n

195 Z line developed HGD or EAC during a median follow-up period of 4.8 years (interquartile range, 3.2-

196 During a median follow-up period of 4.8 years, the time until developmen

197 During the follow-up period of 41.3 +/- 12.6 months, 12/274 patient

198 After a mean follow-up period of 41.4 +/- 29.0 months, patients with

199 During a median follow-up period of 48 (45-52) months, 225 patients (23%

200 Over a follow-up period of 48 weeks, 37 patients remained absti

201 reated with anti-VEGF injections with a mean follow-up period of 5 years.

202 up and 3 or more endoscopies over an average follow-up period of 5.13 years (range, 2-13 years).

203 Over a mean follow-up period of 5.4 years, 58 (38%) of 150 first-tim

204 Over a median follow-up period of 5.63 years, patients with T2DM diagn

205 Over a follow-up period of 501 person-years, 92 incident cases

206 During a median follow-up period of 52 days (IQR: 16-66 days), acute kid

207 o longer required opioid therapy at a median follow-up period of 6 months.

208 After a median follow-up period of 6 years (IQR: 2.3 to 13.9 years), 71

209 ants 73 years of age or older, with a median follow-up period of 6.5 years, and 33 incident cases of

210 Over a mean follow-up period of 6.99 years, 1,282 people died of low

211 of PHT was studied in 548 patients; during a follow-up period of 61.2 months (interquartile range, 39

212 After a mean follow-up period of 7 years, 2 patients had undergone ac

213 Results With a mean follow-up period of 8 years, the mean percent change in

214 f resolution (logMAR; P = 0.081) over a mean follow-up period of 8.2 years.

215 Over a median follow-up period of 8.6 years, overall mortality differe

216 During a median follow-up period of 8.8 (IQR: 4.8-13.3) years, incidence

217 acute myocardial infarction during the full follow-up period of 804 137 person-years, with an adjust

218 After a median follow-up period of 9.1 y, we recorded 6,595 deaths, 5,4

219 rreporting hospitalization events during the follow-up period of a prospective study of patients hosp

220 The mean follow-up period of all eyes was 38.4 +/- 11.2 months (r

221 In a mean follow-up period of approximately 1.6 years, 195 no SVR

222 ssociated optic pathway gliomas (OPGs) and a follow-up period of at least 10 years in a cohort of chi

223 eaths were similar in both groups within the follow-up period of the study.

224 02 had incident cancer and 500 died during a follow-up period of up to 15 years (1995-2010).

225 t case-mix adjusted hazard ratios during the follow-up period of up to 3 years were lower in ischemic

226 iably characterized in recipient plasma over follow-up periods of up to 5 years.

227 There were 37 deaths during the follow-up period, of which none were due to hepatitis B

228 e seizures and epilepsy, before entering the follow-up period on their 10th birthday.

229 te N1 amplitude values was observed over the follow-up period (P < .001) while N1 implicit time remai

230 associated with reporting ongoing IDU in the follow-up period (P < .001), a lack confidence in the ab

231 ar thickness at baseline and over the entire follow-up period (P < .001); best-corrected visual acuit

232 mpared with the placebo group throughout the follow-up period (p = 0.01).

233 associated with reporting ongoing IDU in the follow-up period (p<.001), a lack confidence in the abil

234 ve values (P < .001) and compared in between follow-up periods (P </= .010).

235 During the 9-wk follow-up period, patients recorded daily ratings of fac

236 intained virological control during the same follow-up period (persistent controllers [PCs]).

237 After the 14-day follow-up period, porcine cardiomyocytes were isolated f

238 The follow-up period ranged from 2 weeks to 61 months (10.2

239 The follow-up period ranged from 6 to 18 months.

240 were reported for 16 of these patients, with follow-up periods ranging from 3 to 36 months (average,

241 n of asthma medication dispensing during the follow-up period, relative to the control group (regress

242 Limitations include short follow-up period, self-reported outcomes, and limited ge

243 t diagnosis of Crohn's disease vs during the follow-up period showed that, during treatment, alterati

244 5% (95% CI, 24.5%-62%), in the entire 3-year follow-up period, significant only in the first follow-u

245 s focus on more severe strokes or have short follow-up periods, so the long-term outcomes post-minor

246 diameters increased over a relatively short follow-up period, suggesting the potential for progressi

247 T0), 6 months after surgery (T1), during the follow up period (T2) (mean 15.3 years), and at the end

248 0), 12 months after surgery (T1), during the follow-up period (T2) (15 to 20 years), and at the end o

249 (T2) (15 to 20 years), and at the end of the follow-up period (T3) over 25 to 30 years.

250 T2) (mean 15.3 years), and at the end of the follow-up period (T3) over 25 years.

251 At the end of the follow-up period the number of IOP-lowering medications

252 topped the antithrombotic therapy during the follow-up period (the majority within the first-year pos

253 During a 3-month follow-up period, the intervention was discontinued.

254 During the follow-up period, the magnitude of change in 6MWD differ

255 During a mean 3.3-year follow-up period, the overall incidence of CAC progressi

256 Within the one-year follow-up period, the patients treated via hand-sewn ana

257 o hospital with self-harm during the 6-month follow-up period; the number of times a participant re-p

258 During the entire follow-up period, there was no significant difference in

259 racing underwent surgery during the 12-month follow-up period to promote healing of the fracture.

260 17 US dollars) were assessed over a 24-month follow-up period using a combination of resource-based c

261 espectively) over the course of the 18-month follow-up period using lightweight monitors.

262 efficacy of the treatment at the end of the follow up period was better in group A than in group B.

263 Mortality at the end of the follow up period was the primary outcome.

264 rotid intima-media thickness over the entire follow-up period was 0.0056 mm per year in patients with

265 The median follow-up period was 1.4 (interquartile range: 0.8 to 1.

266 The follow-up period was 12 months.

267 The follow-up period was 12 weeks.

268 At the data cutoff (Aug 7, 2019), the median follow-up period was 12.9 months (IQR 6.2-22.9).

269 The follow-up period was 13 y.

270 The mean +/- standard deviation follow-up period was 14.6+/-3.1 years.

271 ent age was 27.6 +/- 8.0 years, and the mean follow-up period was 38.0 +/- 19.8 months.

272 The median follow-up period was 4.06 years.

273 Mean follow-up period was 5.5 +/- 1.8 (3-12) years.

274 continued to have long-term resolution (mean follow-up period was 548 days).

275 Overall follow-up period was 6.1 +/- 2.3 years.

276 The mean follow-up period was 7.2 years.

277 The follow-up period was a median of 1652 days (IQR: 837-261

278 cidence of readmissions or deaths during the follow-up period was compared between SA children with B

279 ween Feb 6, 2017, and Sept 18, 2017, and the follow-up period was completed on March 1, 2018.

280 The prognosis of eyes over a 5-year (median) follow-up period was determined based on FECD progressio

281 al and morphologic parameters throughout the follow-up period was observed in the eyes that did not u

282 The median follow-up period was ~15 years.

283 of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 yea

284 When our trial ended at the 6-month follow-up period, we found that the intervention had red

285 nes for prostate cancer screening during the follow-up period, we investigated overall cancer, overal

286 (IOP) and complications associated with the follow up period were analyzed and compared.

287 ) of diabetes duration and median (Q1,Q3) of follow-up period were 15.5(8.0) and 8(5, 10) years.

288 1.23; P = .22) and the rates over the entire follow-up period were 52.0% and 57.9%, respectively (odd

289 eted annual diagnostic interviews over a 3-y follow-up period were examined.

290 ession/year of maintenance during the entire follow-up period were extracted and used to analyze the

291 er field (hpf) for greater than 75% of their follow-up period were termed continuous responders (CRs)

292 hpf for less than 75% but 25% or more of the follow-up period were termed intermittent responders (IR

293 iod at high risk of HIV infection during the follow-up period when not taking PrEP; and finally, an i

294 ancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effe

295 ere 68 deaths in LD and 485 in THIN over the follow-up period, with significant difference in mortali

296 on period remained stable during the 8-month follow-up period, with the high-dose regimen continuing

297 8%) of patients were hospitalized during the follow-up period, with the lowest hospitalization in Ita

298 itals remained in the bottom 50% during both follow-up periods, with 50.0% in the bottom 25% of RSSR

299 4 patients (5.4%) died before the end of the follow-up period, without developing the primary outcome

300 d (C(T) ) of <35 or seroconverted during the follow-up period, yielding an attack rate on board of 85